{"id":45906,"date":"2025-11-05T21:45:25","date_gmt":"2025-11-05T13:45:25","guid":{"rendered":"https:\/\/flcube.com\/?p=45906"},"modified":"2025-11-05T21:45:26","modified_gmt":"2025-11-05T13:45:26","slug":"shenzhen-kangtai-biological-products-launches-phase-i-trial-for-infant-influenza-vaccine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45906","title":{"rendered":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine"},"content":{"rendered":"\n<p>China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/300601:SHE\">SHE: 300601<\/a>) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vaccine type<\/strong>: Quadrivalent influenza split\u2011virus<\/li>\n\n\n\n<li><strong>Target population<\/strong>: Infants 6\u202f\u2013\u202f35\u202fmonths<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Induces humoral immunity against four circulating flu strains, preventing influenza caused by vaccine\u2011matching viruses<\/li>\n\n\n\n<li><strong>Delivery<\/strong>: Split\u2011virus formulation, administered via standard intramuscular injection<\/li>\n<\/ul>\n\n\n\n<p>Influenza, an acute respiratory disease, remains a leading cause of morbidity in early infancy. Vaccination is regarded as the most cost\u2011effective preventive measure and forms a key component of public\u2011health strategies to curb outbreaks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-i-trial-highlights\">Phase\u202fI Trial Highlights<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Trial initiation<\/strong> \u2013 Official launch of the first\u2011in\u2011human safety and immunogenicity study.<\/li>\n\n\n\n<li><strong>Enrollment milestone<\/strong> \u2013 First subject enrolled and dosed \u2013 a benchmark for progressing to subsequent phases.<\/li>\n\n\n\n<li><strong>Regulatory context<\/strong> \u2013 Compliance with China\u2019s national vaccine regulatory framework; aligns with the State Administration of Drug Administration (SDA) guidelines for infant vaccines.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio diversification<\/strong> \u2013 Kangtai extends its vaccine catalog into the critical early\u2011infant segment, traditionally dominated by trivalent offerings.<\/li>\n\n\n\n<li><strong>Market positioning<\/strong> \u2013 If clinical success continues, the quadrivalent product could capture a sizable share of China\u2019s growing infant vaccine market, projected to reach USD\u202f30\u202fbillion in 2025.<\/li>\n\n\n\n<li><strong>Future outlook<\/strong> \u2013 Positive safety data will pave the way for Phase\u202fII\/III studies and eventual commercialization, potentially unlocking reimbursement pathways with both public\u2011sector procurement and private\u2011payor systems.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Vaccine Stage<\/th><th>Target Group<\/th><\/tr><\/thead><tbody><tr><td>Kangtai Biological<\/td><td>Phase\u202fI<\/td><td>6\u201135\u202fmonths<\/td><\/tr><tr><td>Beijing Institute of Medicine<\/td><td>Phase\u202fII<\/td><td>6\u201135\u202fmonths<\/td><\/tr><tr><td>Novartis (Fluenz Tetra)<\/td><td>Commercial<\/td><td>6\u201135\u202fmonths (US\/Europe)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Kangtai\u2019s entry into the quadrivalent split\u2011virus niche offers a competitive edge by combining broader strain coverage with a proven split\u2011virus platform, potentially reducing the number of required dose\u2011es across seasons.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-bottom-line\">Bottom\u2011Line<\/h2>\n\n\n\n<p>The successful kickoff of a Phase\u202fI trial positions Shenzhen Kangtai Biological Products as a key player in China\u2019s evolving vaccine ecosystem, with potential ripple effects across the infant influenza vaccine market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u5eb7\u6cf0\u751f\u7269\uff1a\u5173\u4e8e\u56db\u4ef7\u6d41\u611f\u75c5\u6bd2\u88c2\u89e3\u75ab\u82d7\uff086-35-\u6708\u9f84\u4eba\u7fa4\uff09\u5f00\u542f\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u5eb7\u6cf0\u751f\u7269\uff1a\u5173\u4e8e\u56db\u4ef7\u6d41\u611f\u75c5\u6bd2\u88c2\u89e3\u75ab\u82d7\uff086-35 \u6708\u9f84\u4eba\u7fa4\uff09\u5f00\u542f\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-5737cc94-7cfb-49c1-9862-5cf1a8a200a0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u5eb7\u6cf0\u751f\u7269\uff1a\u5173\u4e8e\u56db\u4ef7\u6d41\u611f\u75c5\u6bd2\u88c2\u89e3\u75ab\u82d7\uff086-35-\u6708\u9f84\u4eba\u7fa4\uff09\u5f00\u542f\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u516c\u544a.pdf\">\u5eb7\u6cf0\u751f\u7269\uff1a\u5173\u4e8e\u56db\u4ef7\u6d41\u611f\u75c5\u6bd2\u88c2\u89e3\u75ab\u82d7\uff086-35 \u6708\u9f84\u4eba\u7fa4\uff09\u5f00\u542f\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/\u5eb7\u6cf0\u751f\u7269\uff1a\u5173\u4e8e\u56db\u4ef7\u6d41\u611f\u75c5\u6bd2\u88c2\u89e3\u75ab\u82d7\uff086-35-\u6708\u9f84\u4eba\u7fa4\uff09\u5f00\u542f\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5737cc94-7cfb-49c1-9862-5cf1a8a200a0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45910,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,2361,1007,12],"class_list":["post-45906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-kangtai-biological-products","tag-she-300601","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45906\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45906\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T13:45:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T13:45:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine\",\"datePublished\":\"2025-11-05T13:45:25+00:00\",\"dateModified\":\"2025-11-05T13:45:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0503-1.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Kangtai Biological Products\",\"SHE: 300601\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45906#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45906\",\"name\":\"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0503-1.webp\",\"datePublished\":\"2025-11-05T13:45:25+00:00\",\"dateModified\":\"2025-11-05T13:45:26+00:00\",\"description\":\"China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45906\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0503-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0503-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45906#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45906","og_locale":"en_US","og_type":"article","og_title":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine","og_description":"China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.","og_url":"https:\/\/flcube.com\/?p=45906","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-05T13:45:25+00:00","article_modified_time":"2025-11-05T13:45:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45906#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45906"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine","datePublished":"2025-11-05T13:45:25+00:00","dateModified":"2025-11-05T13:45:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45906"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45906#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp","keywords":["Clinical trial approval \/ initiation","Kangtai Biological Products","SHE: 300601","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45906#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45906","url":"https:\/\/flcube.com\/?p=45906","name":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45906#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45906#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp","datePublished":"2025-11-05T13:45:25+00:00","dateModified":"2025-11-05T13:45:26+00:00","description":"China\u2011based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with its newly\u2011developed quadrivalent influenza split\u2011virus vaccine, designed to protect children aged 6\u201135\u202fmonths. The company announced on Nov.\u202f3\u202f2025 that the first subject has been successfully enrolled, marking the official start of the Phase\u202fI trial.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45906#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45906"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45906#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp","width":1080,"height":608,"caption":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45906#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shenzhen Kangtai Biological Products Launches Phase\u202fI Trial for Infant Influenza Vaccine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0503-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45906"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45906\/revisions"}],"predecessor-version":[{"id":45911,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45906\/revisions\/45911"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45910"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}